Craft

Kaken Pharmaceutical

Stock Price

¥3.9 K

2024-10-29

Market Capitalization

¥147.6 B

2024-10-29

Revenue

¥72 B

FY, 2024

Kaken Pharmaceutical Summary

Company Summary

Overview
Kaken Pharmaceutical is a company focusing on the development and commercialization of pharmaceuticals and medical devices in the orthopedics and dermatology fields. Its products include streptomycin, anti-tuberculosis, anti-osteoarthritis drugs, film-type absorbable adhesion barrier, wound-healing spray, antifungal agents, etc. Additionally, the company is engaged in drug research and discovery in the immune system, nervous system, and infectious diseases areas.
Type
Public
Status
Active
Founded
1948
HQ
Bunkyo City, JP | view all locations
Website
http://www.kaken.co.jp/english/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Hiroyuki Horiuchi, President and Representative Director

    LocationsView all

    1 location detected

    • Bunkyo City, Tōkyō-to HQ

      Japan

    Kaken Pharmaceutical Financials

    Summary Financials

    Revenue (H1, 2025)
    ¥51.4B
    Gross profit (H1, 2025)
    ¥35.4B
    Net income (H1, 2025)
    ¥14.3B
    Cash (H1, 2025)
    ¥67.3B
    EBIT (H1, 2025)
    ¥19.6B
    Enterprise value
    $84.2B

    Footer menu